The molecule is a delivery vehicle
IUPAC: (5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate (morphine 3,6-diacetate) · C21H23NO5 · MW 369.42 g/mol (freebase) · CAS 561-27-3
Diacetylmorphine (diamorphine). A semisynthetic morphinan made by acetylating both hydroxyls of morphine. On its own it barely touches the µ-opioid receptor — heroin is a prodrug. Its job is to smuggle morphine across the blood–brain barrier: the two acetyl groups mask morphine's polar hydroxyls, so heroin is far more lipophilic and floods the brain in seconds, where esterases strip the acetyls back off to release 6-monoacetylmorphine (6-MAM) and morphine — the species that actually drive the pharmacology. Street: smack, H, dope, brown, china white, la blanche.
Heroin's own affinity for the µ-opioid receptor is low — the two acetyl esters block the phenolic 3-OH, the key pharmacophore contact opioids make with MOR. What heroin buys with those esters is lipophilicity: it crosses the blood–brain barrier several-fold faster than morphine. Once in brain tissue, carboxylesterases and pseudocholinesterase rapidly hydrolyze it to 6-monoacetylmorphine (6-MAM), a potent MOR agonist in its own right, and then to morphine. The classic radioligand-binding work (Inturrisi et al., 1983) showed heroin acts through its metabolites — the parent molecule is essentially an inert, brain-penetrant carrier.
At MOR the active species behave as full agonists: they stabilize the receptor's active-state conformation (the same conformation captured in PDB 5C1M with the agonist BU72), which couples to Gi/o proteins. That drives inhibition of adenylyl cyclase (cAMP ↓), opening of GIRK potassium channels (membrane hyperpolarization), and closure of N-type voltage-gated Ca2+ channels (↓ neurotransmitter release). Net effect: neuronal silencing wherever MOR is expressed.
Heroin (3,6-diacetate) → 6-MAM (loses the 3-acetyl) → morphine (loses the 6-acetyl). Carboxylesterases (hCE-1/hCE-2) and butyrylcholinesterase do this in plasma, liver, and brain. The parent's job is transport, not receptor engagement.
6-MAM and morphine restore the free 3-OH and bind the MOR orthosteric pocket (morphine Ki ≈ 1–4 nM, ChEMBL). They lock TM6 in the outward-open agonist conformation, enabling Gi/o coupling.
Gαi inhibits adenylyl cyclase (cAMP ↓); Gβγ opens GIRK channels (hyperpolarization) and closes N-type Ca2+ channels. Presynaptically this cuts neurotransmitter release; postsynaptically it silences firing.
MOR sits on GABAergic interneurons in the VTA. Silencing them disinhibits dopamine neurons projecting to the nucleus accumbens — dopamine ↑ in the reward circuit. The euphoric "rush" is indirect, via removed GABA brake.
MOR in the pre-Bötzinger complex and Kölliker-Fuse/parabrachial nuclei blunts CO2 chemosensitivity and respiratory rhythm. This is the lethal mechanism: apnea, not any peripheral toxicity, is what kills in opioid overdose.
MOR agonism recruits β-arrestin-2 and triggers receptor phosphorylation, internalization, and adenylyl-cyclase superactivation on chronic exposure — the molecular substrate of tolerance and physical dependence. Withdrawal is cAMP rebound.
Heroin has one of the shortest plasma half-lives of any recreational drug — roughly 2–8 minutes — because esterases everywhere in the body attack its ester bonds almost immediately. That is not a flaw; it is the entire design. The acetylation shifts the effective lipophilicity so heroin reaches brain far faster than morphine could, and the fast deacetylation converts it, in situ, into 6-MAM and then morphine — which are more polar and therefore trapped in the CNS. The subjective "rush" tracks the rate of brain 6-MAM formation, which is why route matters so much: IV and smoked heroin produce a near-instant spike, intranasal a blunter one.
Metabolism cascade: a sequential ester-hydrolysis relay converges on morphine, which is then glucuronidated. 6-MAM is the only heroin metabolite that is heroin-specific — its presence in urine distinguishes heroin use from pharmaceutical morphine or codeine, which is why forensic labs hunt for it.
Morphine-6-glucuronide (M6G, marked ★) is a genuinely active, potent MOR agonist that crosses the BBB slowly but accumulates — it prolongs and deepens opioid effect, and because it is renally cleared it accumulates dangerously in renal impairment, a classic cause of delayed, prolonged respiratory depression. Morphine-3-glucuronide (M3G) is inactive at MOR but is pro-excitatory (myoclonus, hyperalgesia at very high exposures). CYP2D6 and CYP3A4 play only minor roles for heroin's metabolites relative to glucuronidation.
Every subjective and clinical effect of heroin is MOR agonism read out in a different brain region. The pharmacology is regionally specific: the same receptor produces euphoria in the limbic system, analgesia in the dorsal horn and midbrain, and — fatally — respiratory arrest in the medulla.
MOR on VTA GABA interneurons is inhibitory; silencing those interneurons disinhibits dopamine neurons projecting to the nucleus accumbens shell. Dopamine surges, driving the intense euphoric rush and powerful reinforcement. Because heroin delivers its payload as a fast spike, the reinforcement signal is steep — a major driver of compulsive use and rapid dependence.
Presynaptic MOR on primary afferent C-fibers in the dorsal horn cuts glutamate/substance-P release; postsynaptic MOR hyperpolarizes projection neurons. Supraspinally, MOR in the periaqueductal gray (PAG) disinhibits descending inhibitory pathways (via the rostral ventromedial medulla) that gate spinal nociception. The result is profound analgesia plus the characteristic affective indifference to pain.
MOR in the pre-Bötzinger complex (respiratory rhythm generator) and the Kölliker-Fuse / parabrachial nucleus blunts both the rhythm and the central chemoreflex to rising CO2. Breathing slows and shallows, hypercapnia and hypoxia build, and unarousable apnea follows. This is dose-dependent, MOR-mediated, and fully reversible by naloxone — which is why every overdose is, in principle, survivable if breathing is supported in time.
Miosis (pinpoint pupils) via MOR disinhibition of the Edinger-Westphal nucleus — a near-pathognomonic overdose sign. Reduced GI motility (constipation, the most persistent, non-tolerating effect) via enteric MOR. Histamine release causes itch, flushing, and warmth. Chronic use suppresses the HPG axis (hypogonadism, amenorrhea). Withdrawal is autonomic rebound: mydriasis, piloerection, diarrhea, lacrimation, yawning — miserable but, unlike alcohol or benzodiazepine withdrawal, very rarely fatal on its own.
Across most of North America the illicit "heroin" supply has been substantially displaced by, or cut with, illicitly manufactured fentanyl and fentanyl analogs (carfentanil, para-fluorofentanyl, and others). Fentanyl is far more potent by mass and, crucially, has a different dose-response and a different time course than heroin. Powders are not homogeneous — the "chocolate chip cookie" problem means one bag can be near-inert and the next lethal. Someone with a heroin-calibrated tolerance has no reliable way to dose an unknown fentanyl concentration by feel.
Xylazine — a veterinary α2-adrenergic agonist sedative — is now a common adulterant in the fentanyl/heroin supply. It deepens sedation and prolongs effect, but it is not an opioid: naloxone does not reverse the xylazine component. Its emergence means an overdose may only partially respond to naloxone (the opioid respiratory depression reverses; the xylazine sedation does not) — so rescue breathing and calling emergency services remain essential even after naloxone.
Wounds: repeated xylazine exposure causes severe necrotic skin ulcers, often distant from injection sites, that can progress to deep tissue loss. This is a distinct, worsening harm layered on top of opioid risk.
Bottom line: assume fentanyl is present, assume potency is unknown, and treat every batch as a new, untested substance regardless of what it is sold as.
The morphinan core is a pentacyclic, bridged, near-rigid scaffold. Once heroin is deacetylated to
morphine or 6-MAM, the pharmacophore that actually enters the MOR pocket has very few rotatable bonds — it arrives
pre-organized. In FlexAID∆S terms this means a small conformational-entropy penalty on binding (ΔS_conf
near zero): the ligand loses little translational/rotational freedom it did not already lack, which is part of why
morphine achieves low-nanomolar affinity (Ki ≈ 1–4 nM) from such a small, ligand-efficient molecule
(LE ≈ 0.55–0.59 in the ChEMBL binding set).
Heroin itself illustrates the entropic cost of the prodrug trick. The two acetyl esters add rotatable bonds and — more importantly — bury the 3-OH hydrogen-bond donor that MOR's active site wants. So heroin pays an enthalpic penalty (a missing key contact) that no amount of favorable entropy can rescue: its intrinsic MOR affinity stays low. The design does not try to bind the receptor better; it trades receptor complementarity for membrane permeability, then lets esterases recover the enthalpic contact in the brain.
On the receptor side, the active-state MOR (PDB 5C1M) represents a low-entropy, transducer-coupled
conformation. In Shannon-entropy terms the apo receptor samples a broad ensemble of TM6 positions
(high H_pocket); a full agonist collapses that ensemble onto the active conformer —
entropy collapse is the structural signature of agonist efficacy. The theoretical binding free energy for
morphine at Ki ≈ 1.8 nM is ΔG = −RT·ln(1/Ki) ≈ −11.9 kcal/mol at 310 K, consistent
with a high-efficacy, pre-organized ligand driving that collapse.
Evidence-based, non-judgmental. Opioid overdose is a respiratory event — it is preventable and reversible if someone is there, has naloxone, and supports breathing.
Naloxone is a competitive MOR antagonist with high receptor affinity — it physically displaces heroin's metabolites (and fentanyl) from MOR and reverses respiratory depression within 1–3 minutes. Intranasal 4 mg or intramuscular 0.4 mg, repeat every 2–3 minutes if no response.
The catch — renarcotization: naloxone's duration (~30–90 min) is shorter than fentanyl's and shorter than 6-MAM+morphine+M6G exposure. The person can slip back into overdose after naloxone wears off. Always call emergency services, stay, and be ready to redose. Support breathing (rescue breaths), place in the recovery position, and expect precipitated withdrawal (agitation, vomiting) on waking — uncomfortable, not dangerous.
| Target / species | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
MOR · morphine
µ-opioid receptor (OPRM1) — active metabolite
|
Ki = 1.8 nM
range 0.88–17 nM
|
Full agonist | |
|
KOR · morphine
κ-opioid receptor (OPRK1)
|
Ki = 64 nM
range 24–260 nM
|
Weak agonist | |
|
DOR · morphine
δ-opioid receptor (OPRD1)
|
Ki = 299 nM
range 140–630 nM
|
Weak agonist | |
|
MOR · 6-MAM
6-monoacetylmorphine — active metabolite
|
low-nM (potent)
~morphine-level (lit.)
|
Full agonist | |
|
MOR · heroin
diacetylmorphine — parent (prodrug)
|
low intrinsic
acts via metabolites
|
Prodrug | |
|
MOR · naloxone
reversal agent (reference)
|
Ki ≈ 1–2 nM
competitive block
|
Antagonist |